$ATRS $2.70 My Nasdaq pick / 90 day up chann
Post# of 99212
Posted On: 12/27/2014 6:35:03 PM
$ATRS $2.70
My Nasdaq pick / 90 day up channel
Multiple FDA-Cleared Devices Give This Company
Extraordinary Upside 12/3/14
96% Buy Composite Opinion
Website
Shares Outstanding: 131.68M
Float: 109.05M
% Held by Insiders: 10.90%
% Held by Institutions: 38.90%
Shares Short (as of Nov 28, 2014): 12.46M
Short Ratio (as of Nov 28, 2014): 14.10
Short % of Float (as of Nov 28, 2014): 10.70%
Shares Short (prior month): 14.02M
10/Q 11/6/14
Summary
Recent trades
Headlines
Wednesday, December 3, 2014
Multiple FDA-Cleared Devices Give This Company Extraordinary Upside-Company Spotlight (Wed, Dec 3)
Antares Pharma to Present at the 25th Annual Oppenheimer Healthcare Conference-Business Wire (Wed, Dec 3)
Tuesday, November 25, 2014
Antares Pharma to Present at the 26th Annual Piper Jaffray Healthcare Conference-Business Wire (Tue, Nov 25)
Friday, November 21, 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Other Events-EDGAR Online (Fri, Nov 21)
Tuesday, November 18, 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financi-EDGAR Online (Tue, Nov 18)
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer-Business Wire (Tue, Nov 18)
Saturday, November 15, 2014
-
ANTARES PHARMA, INC. Financials-EDGAR Online Financials (Sat, Nov 15)
Saturday, November 8, 2014
10-Q for Antares Pharma, Inc.Company Spotlight (Sat, Nov
Thursday, November 6, 2014
Antares Pharma posts 3Q lossAP (Thu, Nov 6)
Q3 2014 Antares Pharma Inc Earnings Release - Before Market Open / CCBN (Thu, Nov 6)
ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fin / EDGAR Online (Thu, Nov 6)
Antares Pharma Reports Third Quarter 2014 Operating and Financial Results / Business Wire (Thu, Nov 6)
Monday, November 3, 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits / EDGAR Online (Mon, Nov 3)
Antares Pharma Announces Last Patient Enrolled in Phase 3 QuickShot® Study Evaluating Testosterone-Deficient Adult Males / Business Wire (Mon, Nov 3)
Thursday, October 30, 2014
Antares Pharma to Host Third Quarter 2014 Operating and Financial Results Conference Call / Business Wire (Thu, Oct 30)
Monday, September 15, 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financi / EDGAR Online (Mon, Sep 15)
Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating Officer / Business Wire (Mon, Sep 15)
Wednesday, September 3, 2014
Antares Pharma to Participate at the Morgan Stanley Healthcare Conference / Business Wire (Wed, Sep 3)
Thursday, August 7, 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fin / EDGAR Online (Thu, Aug 7)
Antares Pharma Reports Second Quarter 2014 Operating and Financial Results / Business Wire (Thu, Aug 7)
My Nasdaq pick / 90 day up channel
Multiple FDA-Cleared Devices Give This Company
Extraordinary Upside 12/3/14
96% Buy Composite Opinion
Website
Shares Outstanding: 131.68M
Float: 109.05M
% Held by Insiders: 10.90%
% Held by Institutions: 38.90%
Shares Short (as of Nov 28, 2014): 12.46M
Short Ratio (as of Nov 28, 2014): 14.10
Short % of Float (as of Nov 28, 2014): 10.70%
Shares Short (prior month): 14.02M
10/Q 11/6/14
Summary
Recent trades
Headlines
Wednesday, December 3, 2014
Multiple FDA-Cleared Devices Give This Company Extraordinary Upside-Company Spotlight (Wed, Dec 3)
Antares Pharma to Present at the 25th Annual Oppenheimer Healthcare Conference-Business Wire (Wed, Dec 3)
Tuesday, November 25, 2014
Antares Pharma to Present at the 26th Annual Piper Jaffray Healthcare Conference-Business Wire (Tue, Nov 25)
Friday, November 21, 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Other Events-EDGAR Online (Fri, Nov 21)
Tuesday, November 18, 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financi-EDGAR Online (Tue, Nov 18)
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer-Business Wire (Tue, Nov 18)
Saturday, November 15, 2014
-
ANTARES PHARMA, INC. Financials-EDGAR Online Financials (Sat, Nov 15)
Saturday, November 8, 2014
10-Q for Antares Pharma, Inc.Company Spotlight (Sat, Nov
Thursday, November 6, 2014
Antares Pharma posts 3Q lossAP (Thu, Nov 6)
Q3 2014 Antares Pharma Inc Earnings Release - Before Market Open / CCBN (Thu, Nov 6)
ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fin / EDGAR Online (Thu, Nov 6)
Antares Pharma Reports Third Quarter 2014 Operating and Financial Results / Business Wire (Thu, Nov 6)
Monday, November 3, 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits / EDGAR Online (Mon, Nov 3)
Antares Pharma Announces Last Patient Enrolled in Phase 3 QuickShot® Study Evaluating Testosterone-Deficient Adult Males / Business Wire (Mon, Nov 3)
Thursday, October 30, 2014
Antares Pharma to Host Third Quarter 2014 Operating and Financial Results Conference Call / Business Wire (Thu, Oct 30)
Monday, September 15, 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financi / EDGAR Online (Mon, Sep 15)
Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating Officer / Business Wire (Mon, Sep 15)
Wednesday, September 3, 2014
Antares Pharma to Participate at the Morgan Stanley Healthcare Conference / Business Wire (Wed, Sep 3)
Thursday, August 7, 2014
ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fin / EDGAR Online (Thu, Aug 7)
Antares Pharma Reports Second Quarter 2014 Operating and Financial Results / Business Wire (Thu, Aug 7)
(0)
(0)